Genmab A/S (GMAB) Stock Forecast & Price Target

$23.02 +0.39 (+1.72%)

As of 01:15 PM Eastern

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
1

Hold
3

Buy
9

Based on 13 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 3 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for GMAB.

Consensus Price Target

$39.17
70.14% Upside

According to the 13 analysts' twelve-month price targets for Genmab A/S, the average price target is $39.17. The highest price target for GMAB is $48.00, while the lowest price target for GMAB is $27.00. The average price target represents a forecasted upside of 70.14% from the current price of $23.02.

Get the Latest News and Ratings for GMAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors.

GMAB Analyst Ratings Over Time

Type	Current Forecast 6/12/24 to 6/12/25	1 Month Ago 5/13/24 to 5/13/25	3 Months Ago 3/14/24 to 3/14/25	1 Year Ago 6/13/23 to 6/12/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$39.17	$39.17	$41.33	$49.25
Forecasted Upside	70.14% Upside	102.83% Upside	101.53% Upside	83.97% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

GMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Genmab A/S Stock vs. The Competition

Type	Genmab A/S	Medical Companies	S&P 500
Consensus Rating Score	2.69	2.81	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	73.07% Upside	5,930.00% Upside	13.11% Upside
News Sentiment Rating	Neutral News See Recent GMAB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/9/2025	HC Wainwright 1 of 5 stars	Raghuram Selvaraju Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $37.00	+105.78%
4/1/2025	Sanford C. Bernstein 3 of 5 stars	J. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
3/11/2025	Truist Financial 3 of 5 stars	Asthika Goonewardene Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$50.00 ➝ $45.00	+122.28%
3/11/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
2/13/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Chang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
2/13/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jonathan Chang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$27.00	+37.13%
2/11/2025	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	V. Floc'h Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
11/8/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$46.00 ➝ $48.00	+110.25%
10/8/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Q. Ding Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
9/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight ➝ Equal Weight	$31.00 ➝ $31.00	+15.63%
Get the Latest News and Ratings for GMAB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.
8/20/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Neutral
7/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Campbell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform
6/27/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$46.00 ➝ $47.00	+83.09%
1/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Sell
12/6/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy
11/10/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
11/8/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Buy
10/12/2023	Nordea Equity Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:32 PM ET.

Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, June 10, 2025. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com.

Genmab A/S
Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

The current stock price is around $21.34, which may present a buying opportunity for investors looking for growth in the biotech sector.
Genmab A/S has recently reported earnings that exceeded analysts' expectations, indicating strong financial performance and potential for future growth.
The company has a solid market capitalization of approximately $13.68 billion, suggesting stability and the ability to invest in research and development.
Analysts have a consensus rating of "Moderate Buy" for the stock, with a price target significantly higher than the current price, indicating potential upside.
Recent investments from institutional investors, such as GTS Securities LLC, reflect confidence in the company's future prospects and may lead to increased stock demand.

Genmab A/S
Bear Case

Investors should be bearish about investing in Genmab A/S for these reasons:

The company has a relatively high price-to-earnings (P/E) ratio of around 12.26, which may suggest that the stock is overvalued compared to its earnings.
Despite recent positive earnings, the revenue reported was significantly lower than analysts' expectations, which could raise concerns about future performance.
One analyst has rated the stock with a sell rating, indicating some skepticism about its short-term prospects.
The stock has experienced volatility, with a 12-month high of $28.96 and a low of $17.24, which may deter risk-averse investors.
Hedge funds and institutional investors only own about 7.07% of the company's stock, suggesting limited institutional confidence compared to other biotech firms.

GMAB Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $39.17, with a high forecast of $48.00 and a low forecast of $27.00.
: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There is currently 1 sell rating, 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GMAB shares.
: According to analysts, Genmab A/S's stock has a predicted upside of 70.14% based on their 12-month stock forecasts.
: Over the previous 90 days, Genmab A/S's stock had 1 downgrade by analysts.
: Genmab A/S has been rated by research analysts at HC Wainwright, and Sanford C. Bernstein in the past 90 days.
: Analysts like Genmab A/S less than other "medical" companies. The consensus rating score for Genmab A/S is 2.69 while the average consensus rating score for "medical" companies is 2.81. Learn more on how GMAB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:GMAB) was last updated on 6/12/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genmab A/S (GMAB) Stock Forecast & Price Target